


Characteristic & Category levels & Switch proportion & P-value\\
\hline
 & PCV7 vs NoVax & 80.0\% & \\
\cline{2-3}
 & PCV10 vs NoVax & 84.8\% & \\
\cline{2-3}
 & PCV13 vs NoVax & 73.1\% & \\
\cline{2-3}
\multirow[t]{-4}{*}{\raggedright\arraybackslash Type of comparison} & PCV13 vs PCV10 & 46.7\% & \multirow[t]{-4}{*}{\raggedleft\arraybackslash 0.020}\\
\cline{1-4}
 & Low & 78.6\% & \\
\cline{2-3}
 & Lower-middle & 79.4\% & \\
\cline{2-3}
\multirow[t]{-3}{*}{\raggedright\arraybackslash Income group} & Upper-middle & 75.2\% & \multirow[t]{-3}{*}{\raggedleft\arraybackslash 0.953}\\
\cline{1-4}
 & Excluded & 80.9\% & \\
\cline{2-3}
\multirow[t]{-2}{*}{\raggedright\arraybackslash Herd effects} & Included & 65.1\% & \multirow[t]{-2}{*}{\raggedleft\arraybackslash 0.055}\\
\cline{1-4}
 & Excluded & 75.8\% & \\
\cline{2-3}
\multirow[t]{-2}{*}{\raggedright\arraybackslash Serotype replacement} & Included & 81.0\% & \multirow[t]{-2}{*}{\raggedleft\arraybackslash 0.784}\\
\cline{1-4}
 & Healthcare/payer & 73.3\% & \\
\cline{2-3}
\multirow[t]{-2}{*}{\raggedright\arraybackslash Study perspective} & Societal & 81.0\% & \multirow[t]{-2}{*}{\raggedleft\arraybackslash 0.335}\\
\hline

